Hospital
Arh Tug Valley Health Services, INC.
Arh Tug Valley Health Services, INC. was paid $33.86M by Medicaid between Sep 2019 and Dec 2024, across 405 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoARH TUG VALLEY HEALTH SERVICES, INC.
PRESTONSBURG, KY 41653
PRESTONSBURG, KY 41653
33aNPI1043878325assigned 06/03/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.86M
24GClaims811,510
24DCodes billed405
24AFirst – last monthSep 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#20 of 36
Median peer was paid$36.08M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,181 | $0.00 | |
| 2020 | 136,540 | $6.01M | |
| 2021 | 197,566 | $7.61M | |
| 2022 | 176,804 | $6.75M | |
| 2023 | 162,589 | $6.64M | |
| 2024incomplete | 136,830 | $6.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 24,203 | 18,664 | $6.70M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.4% | 4,950 | 4,038 | $2.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 7,485 | 3,789 | $2.09M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.4% | 4,656 | 3,890 | $1.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.7% | 12,004 | 9,789 | $1.27M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 27,254 | 19,152 | $1.02M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 13,575 | 8,046 | $770K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 4,801 | 3,757 | $733K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.1% | 440 | 432 | $708K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 2,326 | 2,086 | $624K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 14,119 | 10,649 | $563K |
| 80053 | Comprehensive metabolic panel | 1.6% | 67,138 | 45,338 | $558K |
393 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 9,175 | $506K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.5% | 940 | $503K |
| G0378 | Hospital observation service, per hour | 1.5% | 4,336 | $491K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 1,829 | $460K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 11,476 | $452K |
| 20610 | 1.1% | 4,129 | $360K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 960 | $332K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,294 | $326K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 327 | $300K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,199 | $293K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,484 | $291K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,506 | $279K |
| 47562 | <1% | 152 | $276K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,180 | $275K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,139 | $270K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,400 | $258K |
| 36415 | Collection of venous blood by venipuncture | <1% | 67,543 | $250K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 708 | $248K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,988 | $240K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,462 | $231K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,361 | $226K |
| 59025 | Fetal non-stress test | <1% | 2,608 | $224K |
| 71250 | <1% | 1,515 | $221K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,552 | $218K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,011 | $210K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,783 | $203K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,106 | $201K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17,725 | $200K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,142 | $193K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,138 | $184K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,102 | $178K |
| 72131 | <1% | 1,065 | $175K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 59 | $174K |
| 73110 | <1% | 3,920 | $174K | |
| 87631 | <1% | 3,168 | $169K | |
| 76536 | <1% | 1,978 | $167K | |
| 80061 | Lipid panel | <1% | 15,958 | $161K |
| 73610 | <1% | 3,969 | $159K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,480 | $147K |
| 73564 | <1% | 3,270 | $142K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,410 | $141K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,438 | $129K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,243 | $124K |
| 73030 | <1% | 3,590 | $123K | |
| 73130 | <1% | 2,828 | $118K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,210 | $114K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 272 | $114K |
| 73630 | <1% | 2,715 | $103K | |
| 73562 | <1% | 2,312 | $102K | |
| 70486 | <1% | 550 | $95K | |
| 82652 | <1% | 3,474 | $94K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,905 | $94K |
| 80074 | <1% | 2,764 | $94K | |
| 82607 | <1% | 8,447 | $84K | |
| 73080 | <1% | 1,781 | $78K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,630 | $78K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,539 | $75K |
| 93971 | <1% | 877 | $72K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,511 | $60K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,276 | $59K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,884 | $58K |
| 84484 | <1% | 9,588 | $57K | |
| 20550 | <1% | 1,058 | $54K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,019 | $53K |
| 72141 | <1% | 128 | $53K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,090 | $52K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 147 | $51K |
| 93017 | <1% | 681 | $50K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 183 | $49K |
| 83880 | <1% | 3,407 | $48K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,390 | $47K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,654 | $46K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,558 | $43K |
| 73590 | <1% | 1,134 | $42K | |
| 84439 | <1% | 5,926 | $41K | |
| 73502 | <1% | 1,479 | $41K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 318 | $40K |
| 71271 | <1% | 190 | $40K | |
| 74018 | <1% | 1,199 | $38K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 233 | $37K |
| 76830 | Ultrasound, transvaginal | <1% | 323 | $36K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,462 | $36K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,368 | $35K |
| 73090 | <1% | 952 | $35K | |
| 82746 | <1% | 3,316 | $34K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 88 | $33K |
| 83735 | <1% | 9,783 | $33K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,009 | $32K |
| 99218 | <1% | 100 | $32K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,919 | $32K |
| 96376 | <1% | 2,353 | $29K | |
| 29700 | <1% | 382 | $28K | |
| 81001 | <1% | 17,275 | $28K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 52 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 810 | $28K |
| 96367 | <1% | 715 | $27K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 789 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,700 | $27K |
| 97161 | <1% | 906 | $27K | |
| 76642 | <1% | 578 | $26K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,925 | $26K |
| 84403 | <1% | 1,417 | $26K | |
| 93041 | <1% | 3,339 | $24K | |
| 83690 | <1% | 8,982 | $24K | |
| 94060 | <1% | 232 | $24K | |
| 77065 | Tomosynthesis, mammo | <1% | 494 | $24K |
| 86900 | <1% | 2,251 | $24K | |
| 76775 | <1% | 650 | $23K | |
| 83655 | <1% | 2,332 | $23K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 55 | $20K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 111 | $19K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 235 | $19K |
| 87040 | <1% | 3,703 | $19K | |
| 78227 | <1% | 68 | $19K | |
| 83516 | <1% | 676 | $18K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 974 | $18K |
| 84402 | <1% | 966 | $18K | |
| 82728 | <1% | 1,790 | $17K | |
| 84153 | <1% | 1,363 | $17K | |
| 72100 | <1% | 371 | $17K | |
| 77066 | Tomosynthesis, mammo | <1% | 219 | $16K |
| 81025 | <1% | 4,899 | $16K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 187 | $16K |
| 84270 | <1% | 975 | $15K | |
| 87186 | <1% | 2,775 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,905 | $14K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 162 | $14K |
| 83550 | <1% | 2,444 | $14K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 866 | $14K |
| 82150 | <1% | 4,673 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,360 | $13K |
| 93225 | <1% | 96 | $13K | |
| 84481 | <1% | 1,116 | $13K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,104 | $12K |
| 87077 | <1% | 2,449 | $12K | |
| 83540 | <1% | 2,759 | $12K | |
| 83605 | <1% | 3,045 | $12K | |
| 86038 | <1% | 1,414 | $12K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 345 | $11K |
| 86140 | <1% | 3,906 | $11K | |
| 84702 | <1% | 1,783 | $11K | |
| 82550 | <1% | 4,289 | $11K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 395 | $11K |
| 85610 | <1% | 5,057 | $11K | |
| 29075 | <1% | 137 | $10K | |
| 20551 | <1% | 193 | $10K | |
| 88304 | <1% | 850 | $10K | |
| 0012A | <1% | 530 | $10K | |
| 86200 | <1% | 1,077 | $10K | |
| 84436 | <1% | 2,037 | $9K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 155 | $9K |
| 93242 | <1% | 505 | $9K | |
| 80076 | <1% | 983 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,676 | $8K |
| 87070 | <1% | 1,626 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,410 | $8K |
| 85730 | <1% | 3,319 | $8K | |
| 82043 | <1% | 2,141 | $8K | |
| 84703 | <1% | 2,077 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 108 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 115 | $8K |
| 85378 | <1% | 2,405 | $8K | |
| 74178 | <1% | 17 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 203 | $7K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 843 | $7K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 30 | $7K |
| 82172 | <1% | 363 | $7K | |
| 73000 | <1% | 118 | $6K | |
| 0100U | <1% | 96 | $6K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $6K |
| 73222 | <1% | 12 | $6K | |
| 0011A | <1% | 610 | $6K | |
| 72110 | <1% | 105 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 127 | $6K |
| C1776 | Joint device (implantable) | <1% | 41 | $6K |
| 82570 | <1% | 1,312 | $6K | |
| 88342 | <1% | 164 | $6K | |
| 87076 | <1% | 1,339 | $6K | |
| 73552 | <1% | 144 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 623 | $5K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 45 | $5K |
| 82565 | <1% | 666 | $5K | |
| 84550 | <1% | 1,757 | $5K | |
| 86376 | <1% | 497 | $5K | |
| 93270 | <1% | 190 | $5K | |
| 85652 | <1% | 2,920 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 330 | $5K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 157 | $5K |
| 83013 | <1% | 89 | $5K | |
| 80306 | <1% | 582 | $4K | |
| 82803 | <1% | 539 | $4K | |
| 90715 | <1% | 284 | $4K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 245 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 80 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 578 | $4K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,078 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 970 | $4K |
| 95819 | <1% | 28 | $4K | |
| 93226 | <1% | 74 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,391 | $4K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 32 | $4K |
| 93970 | <1% | 25 | $4K | |
| 84520 | <1% | 434 | $4K | |
| 86850 | <1% | 812 | $3K | |
| 86592 | <1% | 1,038 | $3K | |
| 83970 | <1% | 117 | $3K | |
| 36600 | <1% | 468 | $3K | |
| 84479 | <1% | 728 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 477 | $3K |
| 82553 | <1% | 688 | $3K | |
| 96368 | <1% | 149 | $3K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 56 | $3K |
| 86800 | <1% | 259 | $3K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 470 | $3K |
| 86702 | <1% | 379 | $3K | |
| D1120 | Dental cleaning, child | <1% | 30 | $3K |
| 86431 | <1% | 764 | $3K | |
| J3490 | Unclassified drugs | <1% | 356 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,238 | $3K |
| 83521 | <1% | 230 | $3K | |
| 87590 | <1% | 155 | $3K | |
| 99499 | <1% | 28 | $3K | |
| 73060 | <1% | 98 | $3K | |
| 83615 | <1% | 659 | $3K | |
| 83010 | <1% | 290 | $3K | |
| 25600 | <1% | 33 | $3K | |
| 84146 | <1% | 208 | $3K | |
| 82977 | <1% | 473 | $2K | |
| 86901 | <1% | 1,912 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 38 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,011 | $2K |
| 76870 | <1% | 26 | $2K | |
| 77080 | <1% | 60 | $2K | |
| 76000 | <1% | 37 | $2K | |
| 81003 | <1% | 1,109 | $2K | |
| 86701 | <1% | 382 | $2K | |
| 92523 | <1% | 14 | $2K | |
| 82247 | <1% | 720 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 15 | $2K |
| 80143 | <1% | 242 | $2K | |
| 80348 | <1% | 176 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 643 | $2K |
| 87807 | <1% | 442 | $2K | |
| 84145 | <1% | 215 | $2K | |
| 80069 | <1% | 315 | $2K | |
| J2806 | Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms | <1% | 33 | $2K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 38 | $2K |
| 76937 | <1% | 43 | $2K | |
| 82375 | <1% | 393 | $2K | |
| 81002 | <1% | 734 | $2K | |
| 94729 | <1% | 111 | $2K | |
| 76801 | <1% | 13 | $2K | |
| 86677 | <1% | 173 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 992 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 593 | $2K |
| 87496 | <1% | 85 | $2K | |
| 93246 | <1% | 80 | $2K | |
| 74220 | <1% | 28 | $1K | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 12 | $1K |
| 87581 | <1% | 85 | $1K | |
| 86003 | <1% | 14 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 85 | $1K |
| 29515 | <1% | 20 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,045 | $1K |
| 80050 | General health panel | <1% | 71 | $1K |
| 83001 | <1% | 95 | $1K | |
| 84100 | <1% | 389 | $1K | |
| 72052 | <1% | 15 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 17 | $1K |
| 83002 | <1% | 85 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 40 | $1K |
| 77002 | <1% | 16 | $1K | |
| 83525 | <1% | 123 | $1K | |
| C1769 | Guide wire | <1% | 108 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 765 | $1K |
| 12001 | <1% | 51 | $990.05 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 58 | $944.92 |
| 93880 | <1% | 15 | $932.87 | |
| 74021 | <1% | 18 | $913.22 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 102 | $859.78 |
| 84154 | <1% | 61 | $828.81 | |
| 84156 | <1% | 408 | $827.42 | |
| 93923 | <1% | 12 | $775.85 | |
| 85379 | <1% | 261 | $775.40 | |
| 94726 | <1% | 111 | $773.11 | |
| 83993 | <1% | 47 | $697.52 | |
| 86769 | <1% | 14 | $674.29 | |
| 76942 | <1% | 13 | $660.68 | |
| 82274 | <1% | 87 | $648.87 | |
| 29125 | <1% | 42 | $647.44 | |
| 96523 | <1% | 34 | $643.64 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 58 | $622.01 |
| 29105 | <1% | 23 | $616.88 | |
| 87209 | <1% | 43 | $594.55 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 70 | $566.15 |
| 85651 | <1% | 286 | $561.53 | |
| 82533 | <1% | 52 | $544.81 | |
| 82653 | <1% | 51 | $542.32 | |
| 97010 | <1% | 87 | $529.58 | |
| 73620 | <1% | 13 | $510.40 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 31 | $500.89 |
| 82627 | <1% | 33 | $483.52 | |
| 72040 | <1% | 15 | $481.36 | |
| 82140 | <1% | 87 | $480.19 | |
| 94618 | <1% | 14 | $479.82 | |
| 80349 | <1% | 73 | $445.66 | |
| 82947 | <1% | 170 | $442.40 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 346 | $406.00 |
| A9270 | Non-covered item or service | <1% | 613 | $399.07 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 14 | $393.52 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 311 | $389.96 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 147 | $372.82 |
| 82670 | <1% | 16 | $343.41 | |
| 84478 | <1% | 79 | $342.63 | |
| 84432 | <1% | 25 | $336.44 | |
| 84460 | <1% | 314 | $323.01 | |
| 80324 | <1% | 35 | $322.99 | |
| 87177 | <1% | 43 | $321.34 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 413 | $318.01 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 127 | $314.10 |
| 90686 | <1% | 32 | $303.36 | |
| 64450 | <1% | 23 | $295.47 | |
| 82672 | <1% | 17 | $271.30 | |
| 80337 | <1% | 84 | $268.46 | |
| 82626 | <1% | 18 | $246.59 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 103 | $246.17 |
| 84305 | <1% | 17 | $240.03 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 167 | $237.36 |
| 80369 | <1% | 27 | $235.34 | |
| 86706 | <1% | 26 | $223.46 | |
| 82465 | <1% | 63 | $210.38 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 90 | $200.89 |
| 83883 | <1% | 18 | $197.74 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 83 | $187.45 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 60 | $184.98 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 25 | $183.95 |
| V2632 | Posterior chamber intraocular lens | <1% | 13 | $164.24 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 119 | $153.23 |
| 99406 | <1% | 17 | $151.16 | |
| 83992 | <1% | 39 | $147.88 | |
| 94760 | <1% | 50 | $139.37 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 76 | $128.68 |
| 87075 | <1% | 28 | $110.99 | |
| 80346 | <1% | 35 | $102.72 | |
| 84480 | <1% | 12 | $101.75 | |
| 80299 | <1% | 20 | $94.13 | |
| 82705 | <1% | 26 | $91.56 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 17 | $89.88 |
| 80361 | <1% | 82 | $83.79 | |
| 82248 | <1% | 19 | $83.06 | |
| 80365 | <1% | 64 | $80.97 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 218 | $80.66 |
| 80364 | <1% | 39 | $79.40 | |
| 87205 | <1% | 45 | $76.01 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 19 | $75.00 |
| 80372 | <1% | 39 | $68.80 | |
| 80367 | <1% | 39 | $66.16 | |
| 80373 | <1% | 39 | $66.16 | |
| 80370 | <1% | 39 | $65.92 | |
| 80368 | <1% | 39 | $62.88 | |
| 80366 | <1% | 39 | $60.84 | |
| 84450 | <1% | 66 | $48.30 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 22 | $46.64 |
| 82784 | <1% | 15 | $46.50 | |
| 80331 | <1% | 39 | $41.28 | |
| 80377 | <1% | 39 | $40.80 | |
| 80371 | <1% | 39 | $39.52 | |
| 80334 | <1% | 39 | $36.50 | |
| 80355 | <1% | 39 | $36.18 | |
| 80347 | <1% | 39 | $34.58 | |
| 80354 | <1% | 39 | $33.08 | |
| 80356 | <1% | 39 | $33.08 | |
| 80344 | <1% | 39 | $31.78 | |
| 80338 | <1% | 39 | $30.42 | |
| 85027 | <1% | 15 | $29.70 | |
| 80341 | <1% | 39 | $28.24 | |
| 80358 | <1% | 57 | $27.76 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 43 | $26.71 |
| 80353 | <1% | 53 | $25.76 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 28 | $25.56 |
| 80357 | <1% | 39 | $24.98 | |
| 80326 | <1% | 39 | $23.72 | |
| Q4010 | Cast supplies, short arm cast, adult (11 years +), fiberglass | <1% | 16 | $22.79 |
| 80359 | <1% | 44 | $19.76 | |
| 80360 | <1% | 39 | $19.76 | |
| 84132 | <1% | 13 | $19.04 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $17.12 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 14 | $14.45 |
| 81015 | <1% | 15 | $12.20 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 13 | $12.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 13 | $8.82 |
| 91301 | 0% | 45 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Parent organizationAPPALACHIAN REGIONAL HELATHCARE, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.